Skip to main content
. 2016 Oct 24;16(2):147–156. doi: 10.1074/mcp.M116.061002

Fig. 5.

Fig. 5.

CTDP1 validated as a new BD biomarker in Phase II. A, CTDP1 (boxed in green) showed good sensitivity and high specificity in Phase II validation using the BD focused arrays. B, Boxplot analysis of CTDP1 indicates a similar behavior in HuProt and focused microarray assays. C, Western blotting analysis confirmed that CTDP1 can be specifically identified by BD serum samples but not by TA, AAV, or healthy (Nor) controls.